Authors
Latest:
Marshall Posner, MD, on the Promise of Personalized mRNA Vaccines in Solid MalignanciesMarshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.
Latest:
John Burke, MD, Discuses the Key Findings of the KEYNOTE-564 Trial With Pembrolizumab in High-Risk RCCCancerNetwork®sat down with John Burke, MD, to talk about the topline results in the KEYNOTE-564 trial, which examined the use of pembrolizumab in a population of patients with high-risk renal cell carcinoma.
Latest:
“Promising” Data Support Blinatumomab in CD19+ B-ALL PopulationOverall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Latest:
Alison M. Schram, MD, Reviews Data of Zenocutuzumab in the Phase 2 eNRGy Trial for NRG1 Fusion–Positive CancersAlison M. Schram, MD, spoke about key findings from the phase 2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive advanced solid tumors.
Latest:
Hereditary Renal Tumor Syndromes and the Use of mTOR InhibitorsA 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Clinical Scenario: AE Management for Bispecific Therapy in R/R MMFollowing the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.
Latest:
Caring for Patients With Serious Mental Illness: Guide for the Oncology ClinicianVeronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
Latest:
Clinical Trials in Progress: COBRAPhase 2/3 Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA): a first-in-kind trial seeks to provide level 1 evidence in evaluating the role of ctDNA as a guide for clinicians in the decision to administer adjuvant chemotherapy to patients with stage IIA colon cancer (NRG GI-005) (NCT04068103).
Latest:
Ovarian Cancer Palliative Care May Decrease Readmission Rates, Expert SaysThe use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Characterization of Blood-Based Molecular Profiling in Pancreatic AdenocarcinomaMolecular profiling is being explored in pancreatic adenocarcinoma as a tool to assist with early detection, prognosis, and patient selection in targeted therapy clinical trials.
Latest:
Cross Q&A: Role of Belantamab Mafodotin in MMThe panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Latest:
Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic DiseasesA panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell CancerIn recent years, first-line therapies for metastatic renal cell carcinoma (mRCC) have shifted to a combination of immune checkpoint inhibitors or a combination of antiangiogenesis tyrosine kinase inhibitors (TKIs) and immunotherapy. This has led to a need to address standard-of-care treatment in the second-line setting.
Latest:
Comfort in Whole-Body MRI Testing May Ease Anxiety in LFS PopulationAlthough accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the AppendixMehmet Sitki Copur, MD, and colleagues examine the case of a 65-year-old patient with appendiceal mucinous neoplasms of the appendix who was treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Latest:
Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A ReviewThis review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.
